节点文献

基于MCDA模型构建中药注射剂效益风险评价体系——以双黄连注射剂治疗急性上呼吸道感染为例

Construction of Risk-benefit Assessment System for TCM Injection Based on MCDA Model:Taking Research on Shuanghuanglian Injection in Treatment of Acute Upper Respiratory Tract Infection as a Case

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 卢颖王斯玥刘畅王文文张昱朱文涛

【Author】 Lu Ying;Wang Siyue;Liu Chang;Wang Wenwen;Zhang Yu;Zhu Wentao;College of Management,Beijing University of Chinese Medicine;

【机构】 北京中医药大学管理学院

【摘要】 目的:探讨定性与定量评价相结合评价中药注射剂的有效性、安全性,为综合评估药物价值提供操作路径。方法:以双黄连注射剂治疗急性上呼吸道感染为例,应用多准则决策分析(MCDA)模型探讨构建中药注射剂效益风险评价体系的理论框架。结果:结合中药注射剂的特点,通过确定决策环境、建立价值树、数据收集与处理、定义指标价值、权重赋值、敏感性分析及效益风险评价,综合考量中药注射剂的效益风险,构建系统的效益风险评价体系。结论:基于MCDA模型构建中药注射剂效益风险评价体系,可以比较多种中药注射剂治疗某一疾病的综合价值,为临床合理用药及国家相关药物政策决策提供参考依据。

【Abstract】 Objective: To provide an qualitative and quantitative methods for evaluation of the effectiveness and safety of TCM injections. Methods: Taking research on Shuanghuanglian injection in treatment of acute upper respiratory tract infection as an example,to investigate the construction of traditional Chinese medicine injection risk-benefit assessment system,based on multiple criteria decision analysis( MCDA) model. Results: Combining with the characteristics of TCM injections,comprehensive considerate risk and benefit of TCM injections,to build systematic risk-benefit evaluation system by determining the decision environment,to build a value tree,to collect and process data,rating index,to weight assignment,sensitivity analysis and risk-benefit evaluation. Conclusion: Construction of risk-benefit evaluation system for TCM injection based on MCDA model,could compare comprehensive value of a variety of TCM injection in treatment of a disease and provide reference for clinical rational drug use and relevant national drug policy decisions.

  • 【文献出处】 药物流行病学杂志 ,Chinese Journal of Pharmacoepidemiology , 编辑部邮箱 ,2017年07期
  • 【分类号】R286
  • 【被引频次】7
  • 【下载频次】378
节点文献中: 

本文链接的文献网络图示:

本文的引文网络